6-, 1- AND 2-SUBSTITUTED-1-CARBADETHIAPEN-2-EM-3-CARBOXYLIC ACIDS, PROCESSES FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND INTERMEDIATES

Abstract: Disclosed are 6-, 1- and 2-substituted-1-carbadethiapen-­ 2-em-3-carboxylic acids having the structure: wherein: R¹, R², R⁶, R⁷ and R⁸ are, inter alia, independently selected from the group consisting of hydrogen (R¹ and R² are not hydrogen), alkyl, alkenyl, aryl and aralkyl. Such com­ pounds as well as their pharmaceutically acceptable salt, ester and amide derivatives are useful as antibiotics. Also disclosed are processes for the preparation of such com­ pounds and pharmaceutical compositions comprising such compounds.

Description: 6-, 1- And 2-Substituted-1-Carbadethiapen-2-em-3- Carboxylic Acids, Processes Yor Preparing The Same Pharmaceutical Compositions Containing The Same, And Intermediates BACKGROUND OF THE INVENTION This invention relates to 6-, 1- and 2-substituted l-carbadethiapen-2-em-3-carboxylic acids and derivatives thereof which are useful as antibiotics and which may be represented by the following generic structural EMI1.1 and EMI1.2 wherein R1 R2 R6, R7 and R8 are independently selected from the group consisting of hydrogen, substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, spirocycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; aryl, such as phenyl; araikyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the alkyl has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl;wherein the substituent or substituents relative to the above-named radicals are selected from the group consisting of: amino, mono, di- and triaikylamino, hydroxyl, alkoxyl, mercapto, alkylthio, arylthio such as phenylthio, sulfamoyl, amidino, guanidino, nitro, chloro, bromo, fluoro, cyano and carboxy; and wherein the hetero atom or atoms in the above-named heterocyclic moieties are selected from the group consisting of 1-4 oxygen, nitrogen or sulphur atoms; and wherein the alkyl moieties of the above-recited substituents have 1-6 carbon atoms. This invention also relates to the carboxyl derivatives of I which are antibiotics and which may be reDresented bv the following aeneric structure (I): EMI2.1 and EMI2.2 wherein X' is oxygen, sulphur or NR' (R' = H or lower alkyl having 1-6 carbon atoms); and R31 is, inter alia, representatively selected from the group consisting of hydrogen, conventional blocking groups such as trialkylsilyl, acyl and the pharmaceutically acceptable salt, ester and amide moieties known in the bicyclic ss-lactam antibiotic art; the definition of R3 is given in greater detail below. This invention also relates to processes for the preparation of such compounds (I); pharmaceutical compositions comprising such compounds; and to methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated. EMI3.1 wherein RÚ, Rê, R6, R7 and R8 are independently selected from the group consisting of hydrogen, (RÚ and Rê are not hydrogen), substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; spirocycloalkyl having 3-6 carbon atoms; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the alkyl chain has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl wherein the substituent or substituents relative to the above-named radicals are selected from the group consisting of: amino, mono-, di-, and trialkylamino, hydroxyl, alkoxyl, mercapto, aikylthio, phenylthio, sulfamoyl, amidino, guanidino, nitro, chloro, bromo, fluoroiodo, cyano and carboxy; and wherein the hetero atom or atoms in the above-named heterocyclic moieties are selected from the group consisting of 1-4 oxygen, nitrogen or sulphur atoms; and wherein the alkyl moieties of the above-recited substituents have 1-6 carbon atoms; when R6/R7 is hydrogen and R7/R6 is l-hydroxyethyl, then R8 is not 2-aminoethyl or an N-derivative thereof, and wherein R is a pharmaceutically acceptable ester moiety or a readily removable carboxyl protecting group. 4. A process for preparing a compound having the structure: EMI4.1 and the pharmaceutically acceptable salts and esters thereof; wherein R1, R2, R6, R7 and R8 are independently selected from the group consisting of hydrogen, and substituted and unsubstituted: alkyl having 1-6 carbon atoms, aralkyl, alkenyl and alkynyl having 2-6 carbon atoms, aryl and aralkyl having 6-10 ring carbon atoms and 1-6 carbon atoms in the alkyl chain, heterocyclyl, heterocyclylthio (Re is excluded) aid heterocyclylalkyl having 1-5 hetero atoms selected from 0, N or S in the ring and 1-6 carbon atoms in the alkyl chain, cycloalkyl, spirocycloalkyl, and cycloalkylalkyl having 3 to 6,ring carbon atoms and 1-6 carbon atoms in the alkyl moiety; wherein the substituents on Rl, R2, R , R7 and R6 are selected from chloro, bromo, fluoro, iodo, hydroxyl, amino, mono-, di- and trialkyl substituted amino (each alkyl having 1-6 carbon atoms alkoxyl having 1-6 carbon atoms, guanidino, cyano, amidino and carboxyl; with the proviso that R1, and R2 are not 'hydr9gem, and comprising cyclizing: EMI4.2 wherein is phenyl, and RC is a pharmaceutically acceptable ester moiety or a readily removable blocking group. 5. A process for preparing a compound having the structure: DETAILED DESCRIPTION OF THE INVENTION Compounds of the present invention wherein the 2substitutuent is -SR8 or -H are conveniently prepared according to the following reaction diagram: DIAGRAM I EMI5.1 EMI6.1 In words relative to diagram, the oxidation is accomplished by treating 2 in a solvent such as methylenechloride, methanol, chloroform, or the like, with an oxidizing agent such as Ozone, or the like, at a temperature of from -100 t 0 C for from 0.1 to 4 hours, followed by treating the crude product with an oxidizing agent such as m-chloropercbenzoic acid, hydrogen peroxide peracetic acid, or the like, at a temperature of from 0 C to 1000C for from 1 to 100 hours. po ps ss readily removable protecting group and is defined below. The addition 3#4 is accomplished by treating 3 with 1,1'-carbonyldiimidazole, or the like, in a solvent such as tetrahydrofuran, dimethoxyethane, or the like, at a temperature of from 0 to 50 C, followed by the addition of 1.1 to 3.0 equivalent of (R7O2CCH2CO2)2Mg, at a temperature of from 0 to 50 C for from 1 to 48 hours. R7 z a pharmaceutically acceptable ester society or a readily removable carboxyl protecting groups such as p-nitrobenzyl, benzyl, or the like. Removal of protectinggmup R (4#5) is accomplished by acidic aqueous hydrolysis of 4 in a solvent such as methanol, ethanol, tetrahydrofuran, dioxane, or the like, in the presence of an acid such as hydrochloric, sulfuric, acetic or the like at a temperature of from 0 to 100 C for from 2 to 18 hours. The diazo species 6 is prepared from 5 by treating 5 in a solvent such as CH3CN, CH2C12, THF, or the like, with an azide such as p-carbpxybenzenesulfonylazide, toluenesulfonylazide, methanesulfonylazide, or the like, in the presence of a base such as triethylamine, pyridine, ((:2H5)2NH, or the like, for from 1 to 50 hours at 0-25 C. Cyclization t6 7) is accomplished by treating 6 in a solvent such as benzene, toluene, THF, or the like, at a temperature of from 50-1100C for from 1-5 hours in the presence of a catalyst such as bis (acetylacetonato) Cu (11) [Cu(acac) 21, CuSO4, Cu powder, Rh(OAc)2 or Pd(OAC)2. Alternatively, the cyclization may be accomplished by irradiating 6 through a pyrex filter (a wave lenght greater than 300nm) in a solvent such as benzene, CCl4. diethylether, or the like, at a temperature of from 0-250C for from 0.5 to 2 hours. t"OAcn = acetate3 Establishment of leaving group X (Q-+3) is accomplished by acylating the keto ester t with an acylating agent RX such as p-toluenesulfonic acid anhydride, p-nitrophenylsulfonic acid anhydride, 2,4,6-triisopropylphenylsulfonic acid anhydride, methanesulfonic acid anhydride, toluenesulfonyl chloride, p-bromophenylsulfonyl chloride, or the like, wherein X is the corresponding leaving group such as toluene sulfonyloxy, p-nitrophenylsulfonyloxy, methanesulfonyloxy, p-bromophenylsulfonyloxy and other leaving groups which are established by conventional procedures and which are well known in the art. Typically, the above acylation to establish leaving groups X is conducted in a solvent such as methylene chloride, acetonitrile or dimethylformamide, in the presence of a base such as diisopropylethylamine, triethylamine, 4-dimethylamino-pyridine or the like at a temperature of from -20 to 400C for from 0.5 to 5 hours. The leaving group X of ntermediate ss can also be halogen. The halogen leaving group is established by treating 7 with a halogenating agent such as 3PC12, 3PBr21 (O)3PBr2, otalyl chloride or the like in a solvent such as CH2a2, CH3CN, THF, or the like in the presence of a base such as diisopropylethylamine, triethylamine, or 4-dimethylaminopyridine or the like. [ = phenyl.] The reaction 84 9 is accomplished by treating 8 in a solvent such as dioxane, dimethylformamide, dimethylsulfoxide, acetonitrile, hexamethylphosphoramide, or the like in the presence of an approximately - equivalent to excess of the mercaptan reagent HSR8 wherein R8 as defined above. A representa tive mercaptan reagent is HSCH2 aH 2NH81wherein R8' is hydrogen or a readily removable N-protecting group such as p-nitrobenzyloxycarbonyl, o-nitrobenzyloxy carbonal, or the like in the presence of a base such as sodium hydrogen carbonate, potassium carbonate, triethylamine, diisopropylethylamine, or the like at a temperature of from -40 t 250C br from 1 to 72 hours. ar The mercaptan reagent, ESCE2Ci2NZR , is typically prepared by treating aminoethylmercaptan in the presence of the desired acid chloride in the presence of a base such as sodium bicarbonate, sodiumlydroxide, or the like in a solvent such as aqueous diethylether, aqueous dioxane, aqueous acetone, or the like at a temperature of from 0 to 250C for from 0.5 to 4 hours. The final deblockingstep -+I is accomplished by conventional procedures such as hydrolysis or hydrogenation. Typically 9 in a solvent such as dioxane-water-ethanol, tetrahydrofuran-aqueous dipotassium hydrogen phosphate-isopropanol or the like is treated under a hydrogen pressure of from 1 to 4 atmospheres in the presence of a hydrogenation catalyst such as palladium on charcoal, palladium hydroxide, or the like at a temperature of from 0 to 500C for from 0.5 to 4 hours to provide I. Preparation of Starting Material 1 and With respect to starting reagent 1, its preparation is generally described in J. Amer. Chem. Soc., 74 ,661 (1952) by E.B. Reid and T.E. Gompf, J. Org. Chem., 23,1063 (1958) by R. Ciola and K.L. Burwell, Jr., and Belgium Patent 632,193 (1963) W R. Polster and E. Scharf. The following scheme summarizes the preparation of 1. EMI11.1 In words relative to the above scheme, te diester 12 is prepared by treating the diacid * with thionyl chloride at reflux for two hours followed by reacting with ethanol at 800C for 4 hours. Reduction of the diester 12 with lithium alumium hydride in ether at reflux for 4 hours followed by hydrolysis with 10% NaOH gives diol 13 which on further reaction with thionyl chloride gives dichloride 1ss. The dichloride 14 can be alternatively prepared by treating with ethylene in the presence of alumium chloride. Treatment of the dichloride 14 wLth base such as 2-methylquinoline, DBU or sodium hydroxide in polyethylene glycol gives the expected 3-substituted 1,4-pentadiene 1. Preparation of 2 is summarized in the follow EMI12.1 In words relative to above scheme, the substituted azetidinone 16 is prepared by reacting a 3-substituted 1,4-pentadiene 1 with chlorosulfonylisocyanate at 250C to 600C in a pressure bottle for 3-12 days, then the resulting mixture is hydrolyzed with aqueous sodium sulfite solution between pH 657.5 at 0 C to 250C for from 5 min. to 60 min. Azetidinone 16 is transformed (16#17) to establish the protecting group RO iich may be a triorganosilyl group, such as t-butyldimethylsilyl, t-butyldiphenylsilyl, triphenylsilyl, isopropyldimethylsilyl, for example, or may be 3,4-dimethoxybenzyl, for example. Silyl protection is preferred, and typically R is established by treating 1 in a solvent such as dimethylformamide, acetonitrile, hexamethylphosphoramide, tetrahydrofuran and the like with a silylating agent such as t-butyldimethylchlorosilane, t-butyldiphenylchlorosilane, triphenylchlorosilane, and the like at a temperature of from -2O0cb 250C for from 0.5 to 24 hours in the presence of a base fuch as triethylamine, diisopropylethylamine, or imidazole. Alkylation of 17 provides 18. Typically, 17 is treated with a strong base such as lithium diisopropylamide, sodium hydride, phenyl lithium or butyl lithium and the like in a solvent such as tetrahydrofuran (THF), ether, dimethoxyethane and the like at a temperature of from -80 C to 0 C, whereupon the alkylating agent of choice, R x is added (R6 is as described above and X is Iodo, chloro or bromo; alternatively the alkylating agent may be R6tosylate, R6-mesylate or an aldehyde or ketone such as acetaldehyde and the like) to provide mono- alkylated species 18. When desired dialkylated species 2 may be obtained from 18 by repeating the alkylating procedure, lj. In the foregoing description of the invention, suitable reagents HSR8 (8 # 9) are representatively illustrated by the following list: HSCH2CH2CH2NHCO2PNB, PNBO2CNHCH2CH2CH2SX, EMI14.1 HSCH2CH2NHC02PNB HSC(CH3)2CH2NHCO2PNB, HS#, HSCH2, HSC(CH3)3, HSC3, EMI14.2 and the like ( = phenyl; and PBN = p-nitrobenzyl), CH3SH, CH3CH2SH, CH3(CH2)2SH, (CH3)2CHSH, CH3(CH2)3SH, (CH3)2CH(CH2)2SH, CH2#CHCH2SH, CH#CCH2SH, EMI15.1 #(CH2)3SH(# = phenyl), #(CH2)2SH, HO(CH2) 2SH, H2N(CH2) 2SH, H2N(CH2)3SH, CH3(CH2)2NH(CH2)2SH, EMI15.2 (CH3)2N(CH2)2SH, (CH3CH2)2N(CH2)2SH, HO2C(CH2)2SH, #CH2SH, EMI15.3 (n s 0, 1 or 2; X= C1, Br, F, EMI15.4 EMI16.1 Similarly, suitable alkylating agents for establishing R6 and/or R7 at ultimate ring position 6 (17#18#2) are: CH2CHO,, CH2CH2CHO, CH20, CH3I, CH Br CH3COCH3 Relative to the compounds of the present invention I: EMI17.1 the most preferred values for R1 and i include: ethyl, propyl, isopropyl, cyclopropyl, phenyl benzyl spiro-cyclopropyl The most preferred radicals for R6 and R7 are: R6 = H and R7 is selected from hydroxymethyl, l-hydroxyethyl, l-hydroxypropyl, 2-hydroxypropyl, 2-hydroxyethyl; the most preferred values for R8 are: aminoethylthio, aminopropylthio, aminocyclopropylthio, aminoisopropylthio, amidinoisopropylthio, and quanidinoethylthio. Compounds of the present invention wherein the 2-substituent is R8 or a are conveniently rpepared according to the following reaction diagram: DIAGRAM II EMI18.1 EMI19.1 In words relative to the above reaction diagram, a suitably substituted azetidinone 1 is oxidized by treating 1 in a solvent such as methylenechloride, methanol, chloroform, or the like, with an oxidizing agent such as ozone, or the like, at a temperature of from -100 to OOC for from 0.1 to 4 hours, followed by treating the crude product with an oxidizing agent such as m-chloroperchenzoic acid, hydrogen peroxide, peracetic acid, or the like, at a temperature of from 0 C to 1000C for from 1 to 100 hours. The sequence 2 +z¯ 4 may be achieved ly well-known methods for converting a carboxylic acid to a ketone such as by activating a carboxylic function with dicyclohexylcarbodiimide, ethylchloroformate, 2-fluoropyridine, 1-f luoro-2 , 4-dinitrobenzene, thionyl chloride, oxalyl chloride, or the like followed by the neucleophilic displacement of the leaving qroup with a carbon neucleophile such as R8 > CuMgX , R8MsX NgX , LiCuR821 R28Cd or the like to give the desired ketone (X is bromo or chloro). Or preferably by displacement of the chloride with a thiophenol or 2mercaptopyridine to give a stable thioester 4 wherein X is phenylthio or pyridylthio which may subsequently be reacted with a Grignard reagent to yield the ketone Removal of protecting group R (4-+5) is accomplished by acidic aqueous hydrolysis of 4 in a solvent such as methanol, ethanol, tetrahydrofuran, dioxane, or the like, in the presence of an acid such as hydrochloric, sulfuric, acetic or the like at a temperature of from 0 to 1000C for from 2 to 18 hours. The azetidinone 5 is then reacted with a glyoxyalate ester such as benzyl glyoxalate to give 6. In addition to benzyl, R7 may be any readily removable protecting group or it may be a pharmaceutically acceptable ester. moiety. The reaction 5-+6 is conveniently carried out in a solvent such as benzene, toluene, xylene and the like at a temperature of from about 25 C to reflux for from 2 to 10 hours. There is no criticality as to the precise identity of the solvent, provided only that it adequately solubilizes the reactants and be inert or substantially inert to the desired course of reaction. The halogenation reaction 6#7 may be conducted by any of any of a variety of well-known halogenation means. Suitable reagents include: SOC12, POC13, oxalyl chloride and the like. A preferred means of chlorination involves treating 6 in a solvent such as tetrahydrofuran (THF), ether, CE2C12 aid the like with thionylchloride in the presence of 1 to 2 equivalents (relative to the thionylchloride) of a base such as pyridine, triethylamine, quinoline and the like. Typically, the reaction is conducted at a temperature of from -30 to 250C for from 0.5 to 1 hour. The resulting 7 is isolated, if desired, by conventional procedures for later reaction, 7-+8, The intermediate 8 is prepared by treating 7 in a solvent such as dimethylformamide (DMF), dimethylsulfoxide (DMSO), THF, dimethoxyethane (DME) and the like with 1 to 1.5 equivalents of a phosphine such as triphenylphosphine, tributylphosphine, triethylphosphine, tris-(2-cyanoethyl) phosphine or the like. Typically the reaction is conducted under a nitrogen atmosphere at a temperature of from -20 to 250C., for from 0.5 b 2 hours. Typically, the closure step 8-+9 9 is conducted by heating 8 from 100-1600C in a solvent such as benzene, toluene, dioxane, xylene, or DMF. The carboxyl deblocking step 9(f) may be achieved by a number of well-known procedures such as hydrolysis, hydrogenation, or photolysis of a suitable R' group. Suitable hydrogenation catalysts for deblocking include the platinum metals and their oxides such as palladium on carbon and the like; suitable solvents for the hydrogenation include methanol, dioxane/H20, ethanol/H20, and the like in the presence of hydrogen at a pressure of from 1 to 50 atmospheres; the hydrogenation is typically conducted for from 5 min. to 4 hours at a temperature of about 250C in the optional presence of a mild base such as sodium bicarbonate or the like. The above-mentioned glyoxalate esters used to react with 5 can be prepared by oxidation of the corresponding tartaric acid diesters with oxidants such as periodic acid or lead tetracetate in a solvent such as THF, benzene, methylene chloride at -20 to 250 for 1/2 to 4 hours. The tartarate esters are prepared from dilithio tartarate or disodio tartarate by reaction with R7X wherein X is chloro, bromo or iodo and R' is as defined above in a solvent such as DMF or DMSO at 25 to 700C. for from 4 to 48 hours. As noted above, R7 may be a pharmaceutically acceptable ester moiety which is not subjected to the removal step 9#I. In the generic description of the present invention (I, above), when the 2-substituent is 8 rather than -SR8, the substituent R8 is preferably selected from the group consisting of hydrogen; substituted and unsubstituted: straight and branched loweralkyl having from 1 to 10 carbon atoms; spirocycloalkyl and cycloalkyl having from 3 to 6 carbon atoms; cycloalkylalkyl wherein the cycloalkyl moiety comprises 10 carbon atoms; alkylcycloalkyl wherein the alkyl moiety comprises 1 to 6 carbon atoms and the cycloalkyl moiety comprises 3 to 6 carbon atoms; aryl such as phenyl and naphthyl; aralkyl such as benzyl, phenethyl and the like; heterocyclyl (saturated and unsaturated) comprising monoand bicyclic structures having from 5 to 10 ring atoms wherein one or more of the hetero atoms is selected from oxygen, nitrogen or sulphur, such as thiophene, imidazolyl, tetrazolyl, furyl and the like; heterocyclylalkyl which comprises the immediately preceding heterocyclyl moieties and the alkyl moiety comprises from 1 to 10 carbon atoms; the substituent (or substituents) relative to the above-named radicals is selcted from the group consisting of amino, hydroxyl, cyano, carboxyl, nitro, chloro, bromo, fluoro, lower alkoxy having from 1 to 6 carbon atoms, mercapto, perhaloloweralkyl such as trifluoromethyl, loweralkylthio, guanidino, amidino, sulfamoyl, and N-substituted: sulfamoyl, amidino and guanidino wherein the N-substituent is loweralkyl having from 1 to 6 carbon atoms or aryl having 6-10 carbon atoms. The preferred esters used as protecting groups are those where R is benzyl, p-nitrobenzyl, o-nitrobenzyl, t-butyl, bromo-t-butyl, t-butyldimethylsilyl, trimethylsilyl, trichloroethyl; or R3 represents pharmaceutically acceptable ester moieties such as pivaloyloxymethyl, allyl, methallyl, c2-methylthio) -ethyl, 3-methyl-2-butenyl, p-t-butylbenzyl, 5-indanyl, 3-phthalidyl. The compounds made available by the present invention are valuable antibiotics active against various gram-positive and gram-negative bacteria and, accordingly, find utility in human and veterinary medicine. Such sensitive bacteria representatively include: Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Serratia, Salmonella typhosa, Pseudomonas and Bacterium proteus. The resulting compounds may further be utilized as additives to animal feed, for preserving foodstuffs, and as disinfectants. For example, they may be employed in aqueous compositions in concentrations ranging from 0.1 to 100 parts of antibiotic per million parts of solution in order to destroy and inhibit the growth of harmful bacteria on medical and dental equipment and as bactericides in industrial applications, for example, in waterbased paints and in the white water of paper mills to inhibit the growth of harmful bacteria. These antibiotics may be used alone or in combination as an active ingredient in any one of a variety of pharmaceutical preparations. These antibiotics and their corresponding salts may be employed in capsule form or as tablets, powders or liquid solutions or as suspensions or elixirs. They may be administered orally, intravenously or intramuscularly. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers for example, lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; lubricants, for example, magnesium stearate, talc, polyethylene glycol, silica; disintegrants, for example, potato starch or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of aqueous or oily suspension, solution, emulsions, or syrups; or may be presented as a dry product, for reconstitution with water or other suitable vehicles before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol, syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminum stearate gel or hydrogenated edible oils, for example almond oil, fractionated coconut oil, oily esters, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoates or sorbic acid. Compositions for injection may be presented in unit dose form in ampules, or in multidose container. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use. The compositions may also be prepared in suitable forms for absorption through the mucous membranes of the nose and throat or bronchial tissues and may conveniently take the form of powder or liquid sprays or inhalants, lozenges, throat paints, etc. For medication of the eyes or ears, the preparations may be presented as individual capsules, -in liquid or semi-solid form, or may be used as drops etc. Topical applications may be formulated in hydrophobic or hydrophilic bases as ointments, creams, or lotions. Also, in addition to a carrier, the instant compositions may include other ingredients such as stabilizers, binders, antioxidants, preservatives, lubricators, suspending agents, viscosity agents or flavoring agents and the like. In addition, there may also be included in the compositions other active ingredients to provide a broader spectrum of antibiotic activity. For veterinary medicine the composition may, for example, be formulated as an intramammary preparation in either long or quick-release bases. The dosage to be administered depends to a large extent upon the general health and weight of the subject being treated, and the route and frequency of administration -- the parenteral route being preferred for generalized infections and the oral route for intestinal infections. In general, a daily oral dosage consists of from about 2 to about 600 mg. of active ingredient per kg. of body weight of the subject in one or more applications per day. A preferred daily dosage for adult humans lies in the range of from about 15 to 150 mg. of active ingredient per kg. of body weight. The instant compositions may be administered in several unit dosage forms as, for example, in solid or liquid orally inqestible dosage form. The compositions per unit dosage, whether liquid or solid may contain from 0.1% to 99% of active material, the preferred range being from about 10-60e. The composition will generally contain from about 15 mq. to about 1500 mg. of the active ingredient; however, in general, it is preferably to employ a dosage amount in the range of from about 100 mg. to 1000 mq. In parenteral administration the unit dosage is usually the pure compound in a slightly acidified sterile water solution or in the form of a soluble powder intended for solution. Especially preferred pharmaceutically acceptable salts and esters involving the carboxyl group of compounds of the present invention (I) are disclosed and claimed in co-pendins U.S. Patent Application Serial Number 861,314 (filed 12-16-77) which application is directed, inter alia, to pharmaceutically acceptable salts and esters of the carboxyl group of thienamycin. It is precisely these salts and esters which are preferred in the present invention and they are prepared in a manner analogous to that disclosed in U.S. Patent Application Serial Number 861,314, which is incorporated herein by reference. Thus, especially preferred salts include sodium, potassium, ammonium, and the like; and especially preferred esters include pivaloxymethyl, p-t-butylbenzyl, 5-indanyl, 3-phthalidyl, 3-methyl-2-butenyl, and the like. One should ote that when, in the total synthesis outlined above, R is a pharmaceutically acceptable ester moiety, there is no need for the final deblocking step if it is desired to have the final product I in the form of a pharmaceutically eptable ester. Especially preferred embodiments of the present invention are those, as defined above, except that any unsubstituted amino group borne on radical R8 of Structure I is derivatized according to the teachings of Belgium Patent 848,545 (issued 5-20-77), the resulting amino group being represented thusly (partial structure): EMI28.1 wherein X and Y are defined by the publication; species wherein X is H.or lower alkyl and'Y is are especially preferred. The following examples, illustrate but do not limit the product, process, compositional or method of treatment aspects of the present invention. All reaction temperatures are in OC. EXAMPLE 1 Preparation of 3, 3-Dimethyl-l, 4-pentadiene EMI29.1 procedure a ss,ss-Dimethylglutaric acid (obtained from Aldrich Chemical Company) (one mole), is refluxed for 2 hours with thionyl chloride (68% excess). After removal of excess thionyl chloride, absolute ethanol (109% excess) is added slowly. The mixture is refluxed for 3 hours then distilled to collect the product, diethyl ss,ss-dimethylglutarate (98% yield). To a suspension of lithium alumium hydride (24 g) in ether (860 ml) is added dropwise uth rapid stirring a solution of diethyl ss,-dimethyl- glutarate (124 g in 250 ml ether). The mixture is refluxed for 6 hours, then cooled to room temperature. Water (25 ml) is added slowly. The mixture is then titrated with 10% NaOH until a clear organic layer is obtained. The organic layer is separated, dried over anhydrous sodium sulfate then evaporated in vacua to give the resulting diol as an oil (90% yield), hp. 95 at 1.0 mm. The 3,3-dimethyl-1.5-pentanediol (0.5 mole) is treated with thionyl chloride (1.05 mole) at reflux for 3 hours. After removal of excess thionyl chloride in vacuo, the 3,3-dimethyl-1,5 dichloropentane is obtained (90g yield). 3,3-Dimethyl-1.5-dichloropentane (41 g) is added dropwise at 170-C to a mixture of 48 g of sodium hydroxide and 40 g of polyethylene glycol tetramer and the mixture is distilled to give 3,3 di:nethyl-l,4-pentadiene (66%). Procedure b At -400C, l,3-dichloro-3.methylbutane (50 g) is mixed with alumium chloride (5 g). The ethylene is bubbled through the mixture for 4 hours. The mixture is allowed to warm to room temperature and hydrolyzed with water. The mixture is extracted with ethyl acetate to give 3,3-dimethyl-1,5-dichloropentane. A mixture of 0.5 mole of 3,3-dimethyl-1,5dichloropentane, 2-methylquinoline (2 moles), and sodium iodide (0.1 mole) is refluxed in a flask equipped with aVigreaux column at the top of which is a condenser and take-off. The diolefin 1 is collected during 8 hrs reaction. The product is dried over anhydrous sodium sulfate. EXAMPLE 2 Preparation of 3-methyl-1, 4-pentadiene EMI31.1 Following the procedure of Example 1(a), but replacing ss,ss-dimethylglutaric acid with an equivalent amount of ss-methylglutaric cid, 3-methyl-1;4- pentadiene is obtained. EXAMPLE 3 Preparation of 4-(1,1-dimethyl-pro-2-enyl)azetidin2-one EMI32.1 In a sealed tube, 3,3-dimethyl-1,4-pentadiene (9.6 ) and chlorosulfonyl isocyanate (14.2 g) are allowed to stand at room temperature for 6 days. The resulting mixture is diluted with methylene chloride and added slowly to a stirred aqeous solution which contains 20g of Na2S03 and 50g of K2HPO4 at 0-50C for 30 min. The organic layer is separated and dried over Mg2SO4. After evaporation, the crude product is chromatographed on silica gel GF eluting with EtOAc to give 3. EXAMPLE 4 Preparation of 4-(l-methyl-pro-2-enyl)azetidin-2one EMI33.1 Following the procedure of Example 3, but replacing 3,3-dimethyl-1,4-pentadiene with 3-methyl-1,4- pentadiene, the title compound 4 is obtained. EXAMPLE 5 Preparation of EMI34.1 t-Butyldimethylchlorosilane (7.51 g) is added in one portion to an ice-cold, stirred solution of 4-(l,1- dimethyl-prop-2-ene)-azetidin-2-one 6 6.54 g) and triethylamine C5.04 g) in anhydrous dimethylformamide (100 mull. The reaction mixture is stirred at 0-50C for 1 hour and then allowed to warm to room temperature. Most of the solvent is removed under vacuum to give a residue which is partitioned between diethyl ether t250 ml) and water. The ethereal phase is washed with 2.5N hydrochloric acid (50 ml), water (3x50 ml), and brine, dried with magnesium sulfate, filtered and evaporated under vacuum to provide a crude product which is purified by chromatography on silica gel t208 ether in petroleum ether) to yield 5. EXAMPLE 6 Preparation of g EMI35.1 n-Butyllithium in hexane (26.25 mmol) is added slowly by syringe to a solution of diisopropylamine (26.25 mmol) in anhydrous tetrahydrofuran (100 ml) at -78 C. The resulting solution is stirred for 15 min. prior to the addition of a solution of 5 (25.0 mmol) in anhydrous tetrahydrofuran (25 ml). After stirring for 15 min. at -780C, acetaldehyde (75 mmol) is added by syringe and the resulting solution is stirred at -780C for 5 min. Saturated aqueous ammonium chloride solution (15 ml) is added by syringe and the reaction mixture is allowed to warm to room temperature, then diluted with ether (250 ml) and washed with 2.5N hydrochloric acid solution (2 x 50 ml), water (100 ml) and brine and dried over magnesium sulfate. Solvents are removed in vacuo and the residue is chromatographed on silica gel (1:1, ether: petroleum ether) to give the expected product 6. EXAMPLE 7 Preparation of EMI36.1 A. Trifluoroacetic anhydride (7.5 mmol) is added dropwise by syringe to a solution of dimethylsulfoxide (10 mmol) in anhydrous methylene chloride (15 ml) at -780C. The resulting mixture is stirred at -780C for 20 min. A solution of i (5.0 mmol) in methylene chloride (15 ml) is added by syringe and the cooling bath is removed. After an additional 1 hr., the reaction mixture is diluted with methylene chloride (100 ml), washed xth water (50 ml) and brine and dried over magnesium sulfate. Removal of solvents in vacuo yields crude product which is chromatographed on silica gel (2:1, petroleum ether: ether) to yield 1. EMI37.1 B. n-Butyllithium in hexane (4.10 mmol) is added by syringe to a solution of diisopropylamine (4.10 mmol) in anhydrous tetrahydrofuran (16 ml) at -780C. The resulting solution is stirred at -780C for 15 min. prior to the addition of a solution of l-(t-butyl dimethylsilyl)-4-(1,1-dimethyl-prop-2-enylSazetidin-2- one 5 (2.0 mmol) in anhydrous tetrahydroturan (2 ml). After an additional 15 min. at -780C, the reaction mixture is added via a Teflon tube to a mixture of N-acetylimidazole (4.1 mmol) in anhydrous tetrahydrofuran (16 ml) at -780C. The resulting yellow reaction mixture is stirred at -780C for 15 min., then quenched by addition of saturated aqueous ammonium chloride solution (10 ml). .The reaction mixture is diluted with ether (100 ml) and washed with 2.5N hydrochloric acid solution (25 ml) water (25 ml) and brine. The organic phase is dried over magnesium sulfate and concentrated in vacuo to yield a crude product. This material is chromatographed on silica gel (2:1 petroleum ether: ether) to yield 7. EXAMPLE 8 Preparation of i EMI38.1 K-Selectride (potassium tri- (sec)-butylborohydride) in tetrahydrofuran (4.8 mmol) is added by syringe to a mixture of potassium iodide (2.0 mmol) and 7 (2.0 mmol) in anhydrous ether (20 ml) at room temperature. The resulting mixture is stirred at room temperature for 2.5 hours, then quenched by addition of glacial acetic acid (9.6 mmol). The resulting mixture is diluted with ethylacetate (100 ml) and filtered through celite. Removal of solvents in vacuo gives crude product which is chromatographed on silica gel (1:1 ether: petroleum ether) to yield 1.90 g (95%) of EXAMPLE 9 EMI39.1 ONB = o-nitrobenzyl Under anhydrous conditions at OOC a solution of t (3.50 g) in 60 ml methylene chloride is treated with 4-dimethylaminopyridine (3.32 g) and o-nitrobenzylchloroformate (5.88 g). The mixture is allowed to warm to room temperature and stirred for 1 hr. The resulting mixture is washed with 0.1N HC1, water, brine and water. The organic layer is separated, dried over Na2SO4 and allowed to evaporate in vacuo to give crude products. The crude products, dissolved in 20 ml ether and chilled at -5 C,give the o-nitrobenzyl alcohol (0.5 g) which is separated by filtration. Purification by HPLC (silica gel) eluting with 40% ethylacetate/cyclohexane to gives 7a. EXAMPLE 10 preparation of 8. EMI40.1 A solution of 7 C3.0 mmol) in dry methylene chloride (30 ml) is cooled to -760C (dry re-acetone) and a stream of ozone is bubbled through until the reaction mixture becomes blue. The ozone flow is then stopped and the reaction is purged by bubbling through nitrogen until the blue color disappears. Solid m-chloroperbenzoic acid .0 mmol) is added and the cold bath is removed. When the reaction mixture reaches room temperature, the flask is fitted with a reflux condenser and the mixture is heated at reflux for three days. Removal of solvents in vacuo gives crude product which is chromatographed on silica gel (2% racial acetic acid in methylene chloride) to 8. EXAMPLE 10a Preparation of -8a EMI41.1 The acid 8 (1.0 mmol) is hydrogenated in 30 ml ethyl acetate under 1 atm H2 in the presence of 0.1 mmol of 10% Pd/C at room temperature for 30 min. The mixture is filtered from catalyst. The filtrate is evaporated in vacuo to give 8a. EXAMPLE 11 Preparation of 2 EMI42.1 1,1'-Carbonyldiimidazole(1.10 mmol) z added in one portion to a solution of 8 (1.0 mmol) t anhydrous tetrahydrofuran (5 ml) at room temperature. The resulting solution is stirred at room temperature for 6 hours. In a second flask, magnesium ethoxide (5 mmol) is added in one portion to a solution of the mono-pnitrobenzyl ester of malonic acid (10 mmol) in hydrous tetrahydrofuran (25 ml). The resulting mixture is stirred at room temperature for 1 hr., then the tetrahydrofuran is removed at the pump and the residue is triturated with ether to yield the magnesium salt. This magnesium salt is then added to the first reaction flask and the resulting mixture is shirred at room temperature for 18 hrs. The reaction mixture is then poured into 50 ml of ether, washed with.0.5N hydrochloric acid solution (20 ml), water (20 ml), saturated aqueous sodium bicarbonate solution (20 ml), brine and dried over magnesium sulfate. Removal of solvents in vacuo gives crude product which is chromatographed on silica gel (ether) to yield 9. EXAMPLE 12 Preparation of SQ. EMI44.1 A solution of ss (1.0 mmol) in 20 ml of 9:1 (v/v) methanol-water is cooled to 0 C. Concentrated hydrochloric acid (0.34 ml) is added and the resulting solution is stirred at 0 C for 15 min., then allowed to warm to room temperature. After 2.5 hrs., at room temperature the reaction mixture is diluted with ethyl acetate (25 ml), washed with water (10 ml) and brine, dried over magnesium sulfate and concentrated in vacuo to yield 10. EXAMPLE 13 Preparation of 11. EMI45.1 Triethylamine (263 mg) is added by syringe to a mixture of 10 (253 mg) and p-carboxybenzensulfonylazide (196 mg) in dry acetonitrile (6 mX at OOC. When addition is complete the cooling bath is removed and the reaction mixture is stirred at room temperature for 1 hour. The mixture is then diluted with ethyl acetate CSO ml) and filtered. The filtrate is concentrated in vacuo and the residue is chromatographed on a short silica gel column (ethyl acetate) to yield 11. EXAMPLE 14 Preparation of . EMI46.1 A suspension of 11 (56.4 mg) md rhodium (II) acetate (0.1 mg) in dry benzene (3 ml) is deoxygenated by bubbling through nitrogen for 10 minutes. The mixture is then heated to 780C for 1 hour. During heating the solid starting material gradually goes into solution. The mixture is then cooled, filtered to remove the catalyst, and the filtrate is concentrated in vacuo to yield 12. EXAMPLE 15 Preparation of p-Nitrobenzyloxycarbonylaminoethanethiol EMI47.1 To 600 ml diethyl ether (EtiO) - 75 ml H2O in an ice bath with stirring is added 3.2 g cysteamine hydrochloride (mw a 114; 28.1 mmole). A solution of 7.14 g NaHCO3 (mw r 84; 85 mmole) in 75 ml H2O is added. The ice bath is removed, and at room temperature a solution of 6.75 g p-nitrobenzylchloroformate (mw = 216; 31.3 mmole) in 270 ml Et2O is added dropwise over a period of one hour. After 10 additional minutes, the layers are separated. The ether layer is extracted with 150 ml 0.25 N HC1, and then with 200 ml brine. Each aqueous layer is then backwashed successively with 100 ml Et2O. The combined Et2O layers are dried over anhydrous MgSO4, filtered, and concentrated under a N2 stream. The crystalline residue is slurried in a small amount of ether, filtered, and the pale yellow crystals are dried under high vacuum to give 4.7 g. p-nitrobenzyloxycarbonylaminoethanethiol (65% yield). NMR (CDC13)s 8.18 (d, J=8Hz, aromatic protons ortho to nitro), 7.47 (d, Ja8Hz, aromatic protons meta to nitro), 5.27 (-NH-), 5.20 (s, CH2-NH-), 2.67 (m, -CH2-SH), 1.35 (t, J=8.5Hz, -SH) in ppm downfield from TMS. IR (CHCl3) solution): carbonyl1725 cm 1. M.S.s molecular ion-256, (M-47) at 209, (M-136) at 120, CH2#pNO2 at 136. EXAMPLE 15a Following the procedureeof Example 15, Np-nitrobenzyloxycarbonylaminocyclopropylthio is obtained when an equivalent amount of aminocyclopropylthiol hydrochloride is substituted for the cysteamine hydrochloride of Example 15. EXAMPLE 16 Preparation of 13. EMI49.1 The starting material 12 (51 ¯) is dissolved in acetonitrile (3 ml) and the resulting solution is cooled to OOC. Diisopropylethylamine (22 mg) is added by syringe and the resulting solution is stirred at OOC for 1 minute prior to the addition of a solution of freshly recrystallized p-toluene sulfonic anhydride (51 mg) in dry acetonitrile (1 ml). The resulting solution is stirred at 0 C for 1 hour to provide p-nitrobenzyl 4,4-dimethyl 3- (p-toluene sulfonyloxy)-6-[hydrox.yethyl]-1- azabicyclo [3.2.0]hept-2-en-7-one-2-carboxylate, then cooled to -250C. Diisopropylethylamine (80.5 mg) is added by syringe followed shortly thereafter by a solution of N-p-nitrobenzyloxycarbonylaminocyclopropyl- thiol (40 mg) in 1 ml of dry etonitrile. The reaction mixture is then stored in a refrigerator for 70 hr. The mixture is diluted with 25 ml of ethyl acetate washed with brine and dried over magnesium sulfate. Solvents are removed in vacuo to yield crude product which is chromatographed on a silica gel plate to yield 13. EXAMPLE 17 EMI50.1 A mixture of 13 (10 mg) and 10% Pd/C-Bolhofer type in tetrahydrofuran (2 ml), 0.1M dipotassium hydrogen phosphate solution (1.4 ml) d 2-propanol (0.2 ml) is hydrogenated at 40 psi on the Parr shaker for 30 minutes. The mixture is then filtered and the catalyst is washed with water. The combined filtrate and washings are extracted with ethyl acetate-ethyl ether then concentrated to #3 ml and lyophilized to give 14. EXAMPLE 18 EMI51.1 THF, 20 ml, is placed under N2, treated with 1.54 ml diisopropylamine and cooled to -780C. A solution of n-butyl lithium 1.-97M in hexane (5.6 i) is added dropwise over 5 min. The reaction mixture is stirred at -780C for 10 min. and then treated with 5 (2.14 g) in 15 ml ThF which is added dropwise over 5 min. After another 10 min. hexamethylphosphoramide (1.97 ml) is added. The mixture is stirred another 10 min., then treated with 2 ml of methyl iodide. The reaction mixture is stirred at -780C for 15 min. and allowed to warm to 250C and stirred for 15 min. The reaction mixture is diluted with EtOAc, washed once with pH7 phosphate buffer then dried and evaporated. The residue is chromatographed on silica gel using 25% EtOAc/C6H6 as eluant to give 15. EXAMPLE 19 EMI52.1 To a solution of 1.1 equivalents of freshly Fepared lithium diisopropylamide in anhydrous tetrahydrofuran under a nitrogen atmosphere at -780C is added a solution of 15 in anhydrous tetrahydrofuran which has been cooled to -78 C. After two minutes, the resulting lithium enolate is treated with 3 equivalents of acetaldehyde. The solution is stirred for 30 minutes at -780 and then poured into water. The aqueous phase is saturated with sodium chloride and extracted with ethyl acetate. The combined ethyl acetate solutions are dried over magnesium sulfate and filtered. The filtrate is evaporated under reduced pressure to give the crude product. Purification by chromatography on silica gel using ethyl acetate/benzene gives 16. EXAMPLE 20 Folowing the procedure of the foregoing Exaples, the following substituted azetidinones useful in the preparation of the compound of the present invention are obtained when the suggested subtitution of regents is made. EMI53.1 EMI53.2 <SEP> RÚ <SEP> Rê <SEP> R6 <SEP> R7 <tb> <SEP> #NO2 <tb> <SEP> O <tb> <SEP> # <tb> 1.) <SEP> CH3 <SEP> CH3 <SEP> H <SEP> #-CH2OC-OCH22.) <SEP> CH3 <SEP> Et <SEP> H <SEP> CH3 <tb> <SEP> O <tb> <SEP> # <tb> 3.) <SEP> CH3 <SEP> # <SEP> H <SEP> C6H5C <tb> EMI54.1 <SEP> RÚ <SEP> Rê <SEP> R6 <SEP> R7 <tb> <SEP> O <tb> <SEP> # <tb> 4.) <SEP> CH3 <SEP> #-CH2 <SEP> H <SEP> CH3C <tb> 5.) <SEP> CH3 <SEP> CH3 <SEP> CH3 <SEP> # <SEP> OH <tb> <SEP> # <SEP> H <SEP> # <tb> <SEP> CH3 <SEP> CH3 <tb> 6.) <SEP> CH3 <SEP> Ph <SEP> H <SEP> N3 <tb> <SEP> #CH3 <tb> 7.) <SEP> CH3 <SEP> CH3CH2CH2 <SEP> CH3 <SEP> OCO2CH2-# <tb> <SEP> #CH3 <SEP> NO2 <tb> 8.) <SEP> Et <SEP> Et <SEP> CH3CH2 <SEP> OCO2CH2-# <tb> <SEP> NO2 <tb> EMI55.1 <SEP> RÚ <SEP> Rê <SEP> R6 <SEP> R7 <tb> <SEP> O <tb> <SEP> # <tb> 9.) <SEP> CH3 <SEP> H <SEP> CH3 <SEP> CH3C <tb> <SEP> NO2 <tb> 10.) <SEP> Et <SEP> CH3 <SEP> H <SEP> OCO2CH2# <tb> <SEP> # <tb> <SEP> CH3 <tb> <SEP> NO2 <tb> 11.) <SEP> Et <SEP> Et <SEP> CH3 <SEP> OCO2CH2# <tb> <SEP> # <tb> <SEP> CH3 <tb> EMI56.1 <SEP> RÚ <SEP> Rê <SEP> R6 <SEP> R7 <tb> <SEP> NO2 <tb> 12.) <SEP> # <SEP> CH3 <SEP> CH3 <SEP> OCO2CH2# <tb> <SEP> # <tb> <SEP> NO2 <tb> 13.) <SEP> CH3 <SEP> CH3 <SEP> H <SEP> OCO2CH2# <tb> <SEP> # <tb> <SEP> CH2 <SEP> CH214.) <SEP> CH3 <SEP> Et <SEP> H <SEP> OCH2SCH3 <tb> <SEP> # <tb> <SEP> NO2 <tb> 15.) <SEP> H <SEP> # <SEP> H <SEP> OCO2CO2CH2# <tb> <SEP> # <tb> <SEP> Ph <tb> 16.) <SEP> CH3 <SEP> CH3 <SEP> H <SEP> Ph <SEP> # <tb> <SEP> CH3 <tb> EMI57.1 <SEP> RÚ <SEP> Rê <SEP> R6 <SEP> R7 <tb> 17.) <SEP> CH3 <SEP> CH3 <SEP> H <SEP> N# <tb> 18.) <SEP> CH3 <SEP> H <SEP> H <SEP> # <tb> <SEP> N <tb> <SEP> NO2 <tb> 19.) <SEP> CH3 <SEP> Et <SEP> H <SEP> SCO2CH2# <tb> <SEP> # <tb> <SEP> CH3 <tb> 20.) <SEP> RÚ+Rê=spirocyclopropyl <SEP> H <SEP> OCO2PNB <tb> <SEP> # <tb> 21.) <SEP> CH2CH2Br <SEP> CH3 <SEP> H <SEP> OCO2PNB <tb> <SEP> # <tb> EXAMPLE 21 Following the foregoing text and Examples, the following species (I) are obtained when the ss-lactams of Example 20 are carried through the standard procedure (Examples 10-14) to the corrsponding bicyclic keto ester, followed by establishment of the thio side chain of choice and deblocking (Examples 16 and 17). EMI58.1 EMI58.2 Compound <SEP> RÚ <SEP> Rê <SEP> R6 <SEP> R7 <SEP> R <SEP> R8 <tb> 1.) <SEP> CH3 <SEP> -CH3 <SEP> H <SEP> HOCH2 <SEP> Na+ <SEP> #NH2 <tb> 2.) <SEP> Et <SEP> -CH3 <SEP> H <SEP> -CH3 <SEP> Na+ <SEP> #NH2 <tb> <SEP> O <SEP> NH <tb> <SEP> # <SEP> # <tb> 3.) <SEP> CH3CH2CH2 <SEP> -CH3 <SEP> H <SEP> #-C <SEP> H <SEP> #NHCH <tb> <SEP> O <SEP> NH <tb> <SEP> # <SEP> # <tb> 4.) <SEP> # <SEP> H <SEP> H <SEP> CH3C <SEP> K+ <SEP> #NHC-NH2 <tb> EMI59.1 Compound <SEP> RÚ <SEP> Rê <SEP> R6 <SEP> R7 <SEP> R <SEP> R8 <tb> 5.) <SEP> # <SEP> -CH3 <SEP> H <SEP> (CH3)2C(OH)- <SEP> CH2OCCMl3 <SEP> -CH3 <tb> 6.) <SEP> PhCH2 <SEP> CH3 <SEP> H <SEP> CH3CH(N3)- <SEP> H <SEP> #NH2 <tb> 7.) <SEP> Ph <SEP> CH3 <SEP> -CH3 <SEP> CH3CH(OH)- <SEP> H <SEP> #NH2 <tb> 8.) <SEP> CH3 <SEP> CH3 <SEP> CH3CH2- <SEP> HOCH2- <SEP> -CH2-#+ <SEP> -C2H5 <tb> <SEP> O <tb> <SEP> # <tb> 9.) <SEP> CH3# <SEP> CH3 <SEP> CH3 <SEP> CH3C- <SEP> H <SEP> -CF2CH2NH2 <tb> <SEP> CH3 <tb> 10.) <SEP> C4H9 <SEP> -CH2CH2NH2 <SEP> H <SEP> #CH2CH(OH)- <SEP> H <SEP> -Ph <tb> 11.) <SEP> Et <SEP> CH3CH2 <SEP> CH3 <SEP> CH3CH(OH)- <SEP> H <SEP> #CH2NH2 <tb> EMI60.1 Compound <SEP> RÚ <SEP> Rê <SEP> R6 <SEP> R7 <SEP> R <SEP> R8 <tb> 12.) <SEP> CH3 <SEP> # <SEP> CH3 <SEP> HOCH2- <SEP> Na+ <SEP> CH3 <tb> 13.) <SEP> # <SEP> CH3 <SEP> H <SEP> CH3CH(OH)CH2- <SEP> (C2H5)4N+ <SEP> CH2NH2 <tb> 14.) <SEP> #CH2NH2 <SEP> CH3 <SEP> H <SEP> CH3CH(OCH2SCH3)- <SEP> H <SEP> CH2#NH2 <tb> <SEP> OH <SEP> NH <tb> <SEP> # <SEP> # <tb> 15.) <SEP> Ph <SEP> CH3 <SEP> H <SEP> #CH <SEP> H <SEP> CH2CH2C-NH2 <tb> 16.) <SEP> CH3 <SEP> CH3CH(CH3)- <SEP> H <SEP> # <SEP> H <SEP> #NH <tb> 17.) <SEP> CH3 <SEP> CH3 <SEP> H <SEP> N# <SEP> Na+ <SEP> #CH2H <tb> <SEP> NH2 <tb> 18.) <SEP> Et <SEP> CH3 <SEP> H <SEP> N# <SEP> H <SEP> #N <tb> 19.) <SEP> CH3 <SEP> CH3 <SEP> H <SEP> CH3CH(SH)- <SEP> K+ <SEP> -CH3 <tb> <SEP> NH <tb> <SEP> # <tb> 20.) <SEP> RÚ+Rê=spirocyclopropyl <SEP> H <SEP> CH3CH(OH)- <SEP> Na <SEP> -CH2CH2NHC-H <tb> EXAMPLE A Preparation of 8. EMI61.1 A solution of 7 C3.0 mmol) in dry methylene chloride (30 mll is cooled to -780C (dry re-acetone) and a stream of ozone is bubbled through until the reaction mixture becomes blue. The ozone flow is then stopped and the reaction is purged by bubbling through nitrogen until the blue color disappears. Solid m-chloroperbenzoic acid .0 mmol) is added and the cold bath is removed. When the reaction mixture reaches room temperature, the flask is fitted with a reflux condenser and the mixture is heated at reflux for three days. Removal of solvents in vacuo gives crude product which is chromatographed on silica gel (28 racial acetic acid in methylene chloride) to 8. EXAMPLE B Preparation of 11 EMI62.1 The azetidinone 10 C0,851 g) is dissolved in 20 ml CH2C12 and cooled to 00C under N2. Oxalyl chloride (0.8 ml) is added dropwise over 5 min. followed by 1 drop of DMF. The mixture is stirred at 0 for 5 min. and then at 250C for 15 min. The solvent and excess oxalyl chloride are evaporated under reduced pressure. The residue is the desired acid chloride. The acid chloride is dissolved in 20 ml CH2C12 and cooled to 00, under N2. Mercapatopyridine (0.4 g) and pyridine (0.8 ml) are added. The reaction mixture is stirred at 0 C for 5 min., then allowed to warm to room temperature. The mixture is diluted with CH2C12 and washed with water, dried over Na2SO4 and evaporated in vacuo. The residue is chromatographed on silica gel using 50% EtOAc/C6H5 as eluant, to give the thio ester 11. EXAMPLE C EMI63.1 The thio ester 12 (64 mg) in 2 ml THF is treated with a solution of cyclopropyl magnesium bromide C0.25 M in Et2O, 2.6 ml). The mixture is allowed to stir at 0 for 1 hour. A saturated NH4C1 aqueous solution is added and the mixture is allowed to stir for 10 minutes. The organic phase is separated. The aqueous phase is extracted twice with CH2C12. The combined organic extracts are dried and evaporated. Preparative t.l.c. of the residue using silica gel and 50% EtOAc/benzene gives the desired product 13. EXAMPLE D EMI64.1 A solution of 12 (1.0 mmol) in 20 ml of MeOH is cooled to 0 OC. Hydrochloric acid (2.5N, 1 eq) is added and the resulting solution is stirred at 0 C for 1 hr., then allowed to warm to room temperature. The mixture is diluted with ethyl acetate C25 ml), washed with water (10 ml) and brine, dried over magnesium sulfate and sncentrated in vacuo to give 13. EXAMPLE E Preparation of EMI65.1 The azetidinonel3 (0.8 g) and p-nitrobenzyl glyoxylate hydrate (1.5 g) are refluxed in benzene t100 ml) for 6 hrs. The reaction apparatus is equipped with a Dean-Stark trap for removal of water azeotropically. The solution is cooled, evaporated, and chromatographed on silica gel eluting with 50% EtOAc/cyclohexane to give product 14. EXAMPLE F Preparation of EMI66.1 Under N2, at -200C, the carbinal 14 (0.8 g) in 5 ml THF is treated with thionyl chloride (204tug) and pyridine (136 mg) for 10 min., then the mixture is allowed to warm to room temperature. The mixture is diluted with 10 ml benzene and filtered from solids. Evaporation of filtrate in vacuo gives the expected chloride which is then treated with triphenylphosphine (468 mg) in 5 ml DMF and stirred at room temperature for 1 hr. After evaporation of solvent in vacuo, the residue is dissolved in 70 ml CH2C12 and washed with 0.5M sodium phosphate buffer (pH 69). The organic layer is separated, dried over MgSO4 and chromatographed on silica gel eluting with 30% ethyl acetate/CH2C12 to give 16. EXAMPLE G Preparation of EMI67.1 The ylide 1 (61 mg) is dissolved in 3 ml xylene and heated at 1400 under N2 tr 1.5 hr. The mixture is cooled to 250C. Xylene is removed under reduced pressure. The residue chromatographed on silica gel plates gives the desired product 17. EXAMPLE H Preparation of 18 EMI68.1 The carbapenem ester 17 (10 mg) is dissolved in 1 ml dioxane. To the solution is added 1 ml water 0.2 ml ethanol, 10 mg NaHCO3, and 5 mg 10% Pd/C. The mixture is hydrogenated for 20 min. at 40 psi. The mixture is filtered from catalyst, and the filtrate is extracted with 3 x 5 ml ether. The aqueous layer is separated and chromatographed on an XAD-2 column eluted with water then 10% THF/water to give the title compound 18. EXAMPLE I Following the procedures by the foregoing text and Examples, the following 1,2,6-substituted-1-carbadethiapen-2-em-3-carboxylic acid (I) are obtained by strict analogy when the suggested substitution of reagents is made. EMI69.1 TABLE V EMI69.2 Compound <SEP> R6 <SEP> R7 <SEP> R8 <SEP> RÚ <SEP> Rê <SEP> R0 <tb> <SEP> NH <tb> <SEP> # <tb> 1.) <SEP> CH3 <SEP> OH <SEP> H <SEP> -#-CH2NHCCH3 <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> 2.) <SEP> CH3 <SEP> OH <SEP> H <SEP> -# <SEP> CH2CH2NH2 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> 3.) <SEP> CH3 <SEP> OH <SEP> H <SEP> -#-NH2 <SEP> CH3 <SEP> C2H5 <SEP> H <tb> <SEP> H <SEP> # <tb> EMI70.1 Compound <SEP> R6 <SEP> R7 <SEP> R8 <SEP> RÚ <SEP> Rê <SEP> R0 <tb> <SEP> O <tb> <SEP> # <tb> 4.) <SEP> CH3 <SEP> OH <SEP> H <SEP> -#-CH2NH2 <SEP> CH3 <SEP> # <SEP> -CH2OCCMe3 <tb> <SEP> H <SEP> # <tb> <SEP> NH <tb> <SEP> # <tb> 5.) <SEP> CH3 <SEP> OH <SEP> H <SEP> -#-CH2NHC-NH2 <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> <SEP> NH <tb> <SEP> # <tb> 6.) <SEP> CH3 <SEP> OH <SEP> H <SEP> -#-CH2CH2NHC-CH3 <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> <SEP> CH3 <tb> <SEP> # <tb> 7.) <SEP> CH3 <SEP> OH <SEP> H <SEP> -CH2CH2CH2NH2 <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> 7a.) <SEP> CH3 <SEP> OH <SEP> H <SEP> -#-CH2NH2 <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> EMI71.1 Compound <SEP> R6 <SEP> R7 <SEP> R8 <SEP> RÚ <SEP> Rê <SEP> R0 <tb> <SEP> NH <tb> <SEP> # <tb> 8.) <SEP> CH3 <SEP> OH <SEP> H <SEP> -CH2CH2CH2NHC-H <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> <SEP> -NH2 <tb> 9.) <SEP> CH3 <SEP> OH <SEP> H <SEP> # <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> 10.) <SEP> CH3 <SEP> OH <SEP> CH3 <SEP> -# <SEP> NH <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <SEP> \ <SEP> # <tb> <SEP> NHCH <tb> <SEP> NH <tb> <SEP> # <tb> 11.) <SEP> CH3 <SEP> OH <SEP> CH3 <SEP> -CH=CH-CH2NHC-CH3 <SEP> C2H5 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> <SEP> NH <tb> <SEP> # <tb> 12.) <SEP> CH3 <SEP> OH <SEP> H <SEP> -CH=CH-CH2NHC-CH3 <SEP> C2H5 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> 13.) <SEP> CH3 <SEP> OH <SEP> H <SEP> -CH2-# <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> EMI72.1 Compound <SEP> R6 <SEP> R7 <SEP> R8 <SEP> RÚ <SEP> Rê <SEP> R0 <tb> 14.) <SEP> CH3 <SEP> OH <SEP> H <SEP> -CH2-# <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> 15.) <SEP> CH3 <SEP> OH <SEP> H <SEP> -CH2-#CH3 <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> 16.) <SEP> CH2OH <SEP> H <SEP> -CH2-# <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> # <tb> <SEP> CH3 <tb> 17.) <SEP> CH2OH <SEP> CH3 <SEP> -#-CH2NH2 <SEP> CH3 <SEP> Et <SEP> H <tb> <SEP> NH <tb> <SEP> # <tb> 18.) <SEP> CH2OH <SEP> CH3 <SEP> -CH2CH2NHCH <SEP> CH3 <SEP> Et <SEP> H <tb> 19.) <SEP> CH3 <SEP> NH2 <SEP> H <SEP> CH3 <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> 20.) <SEP> CH3 <SEP> NH2 <SEP> H <SEP> -# <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> EMI73.1 Compound <SEP> R6 <SEP> R7 <SEP> R8 <SEP> RÚ <SEP> Rê <SEP> R0 <tb> 21.) <SEP> CH3 <SEP> NH2 <SEP> H <SEP> # <SEP> C2H5 <SEP> CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> <SEP> CH3 <tb> <SEP> / <tb> 22.) <SEP> -C2NH2 <SEP> CH3 <SEP> -CH <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> \ <tb> <SEP> CH3 <tb> 23.) <SEP> C2H5 <SEP> NH2 <SEP> H <SEP> #-OMe <SEP> CH3 <SEP> CH2CH2CH3 <SEP> H <tb> <SEP> H <SEP> # <tb> <SEP> CH3 <tb> <SEP> # <tb> 24.) <SEP> C2H5 <SEP> OH <SEP> H <SEP> -CH2CH-NH2 <SEP> CH3 <SEP> -# <SEP> H <tb> <SEP> H <SEP> # <tb> <SEP> CH3 <SEP> CH2NH2 <tb> <SEP> # <SEP> / <tb> 25.) <SEP> CH##OH <SEP> H <SEP> -# <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> # <SEP> # <tb> <SEP> CH3 <SEP> H <tb> <SEP> CH3 <tb> <SEP> / <tb> 26.) <SEP> OH <SEP> H <SEP> -#H-CH2NH2 <SEP> CH3 <SEP> CH3 <SEP> H <tb> <SEP> # <tb> <SEP> # <SEP> # <tb> 27.) <SEP> OH <SEP> H <SEP> -CH2CH2NH2 <SEP> -CH2-CH2 <SEP> # <tb> <SEP> # <SEP> # <tb> EXAMPLE J Preparation 'of Pharmaceutical Compositions One such unit dosage form is prepared by mixing 120 mg of l,1-dimethyl-6-(l-hydroxymethyl)-2- t2-aminocyclopropylthio)-1-carbadethiapen-2-em-3-carboxylic acid with 20 mg of lactose and 5 mg of magnesium stearate and placing the 145 mg. mixture into a No. 3 gelatin capsule. Similarly, by employing more of the active ingredient and less lactose, other dosage forms can be put up in No. 3 gelatin capsules and should it be necessary to mix more than 145 mg. of ingredients together larger capsules such as compressed tablets and pills can also be prepared. The following examples are illustrative of the preparation of pharmaceutical formulations: TABLET PER TABLET 1,1-dimethyl-6-(1-hydroxymethyl) 2-(2-aminocyclopropylthio} carbadethiapen-2-em-3-carboxylic acid 125 mg. Dicalcium Phosphate 192 mg. Cornstarch, U.S.P. 6 mg. Lactose, U.S.P. 190 mg. Magnesium Stearate Balance The active ingredient is blended with the dicalcium phosphate, lactose and about half of the cornstarch. The mixture is then granulated with 15% cornstarch paste (6 mg) d rough-screened. It is dried at 450C and screened again through No. 16 screens. The balance of the cornstarch and'the magnesium stearate is added and the mixture is compressed into tablets, approximately 0.5 tch in diameter each weighing 800 mg. PARENTERAL SOLUTION Ampoule: 1,1-dimethyl-6-(1-hydroxymethyl)-2 (2-aminocyclopropylthio)-1-carbadethiapen-2-em-3-carboxylic acid 500 mg. Diluent: Sterile Water for Injection 5 cc. OPHTHALMIC SOLUTION 1, l-dimethyl-6- (1-hydroxymethyl) -2- (2-aminocyclopropylthio)-l-carbadethia- pen-2-em-3-carboxylic acid 100 mg. Hydroxypropylmethyl cellulose 5 mg. Sterile Water to 1 ml. OTIC SOLUTION 1,1-dimethyl-6-(1-hydroxymethyl)-2 (2-aminocyclopropylthio) -1-carbadethia- pen-2-em-3-carboxylic acid 100 mg. Benzalkonium chloride 0.1 mg. Sterile Water to 1 ml. TOPICAL OINTMENT 1,1-dimethyl-6-(1-hydroxymethyl)-2 (2-aminocyclopropylthio) -1-carbadethia- pen-2-em-3-carboxylic acid 100 mg. Polyethylene Glycol 4000 U.S.P. 400 mg. Polyethylene Glycol 400 U.S.P. 1.0 gram.

Claims: WHAT IS CLAIMED IS 1. A compound having the structure: EMI76.1 and the pharmaceutically acceptable salts and esters thereof; wherein RÚ, Rê, R6, R7 and R8 are independently selected from the group consisting of hydrogen, (R1 aid R2 are not hydrogen), substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl toieties; spirocycloalkyl having 3-6 carbon atoms; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the alkyl chain has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl wherein the substituent or substituents relative to the above-named radicals are selected from the group consisting of: amino, mono-, di-, and trialkylamino, hydroxyl, alkoxyl, mercapto, alkylthio, phenylthio, sulfamoyl, amidino, guanidino, nitro, chloro, bromo, fluoroiodot cyano and carboxy; and wherein the hetero atom or atoms in the above-named heterocyclic moieties are selected from the group consisting of 1-4 oxygen, nitrogen or sulphur atoms; and wherein the alkyl moieties of the above-recited substituents have 1-6 carbon atoms; when R6/R7 is hydrogen and R7/R6 is l-hydroxyethyl, then R8 is not 2-aminoethyl or an N-derivative thereof. 2. A compound according to Claim 1 wherein R1 and R2 are selected from alkyl, cycloalkyl, spirocycloalkyl, benzyl or phenyl; and R6 is H or methyl and R7 is alkyl, phenyl, aralkyl or hydroxyl-sub stituted alkyl, phenyl or aralkyl. 3. A compound according to Claim 2 wherein R1 and Rê are selected from spirocyclopropylt methyl, ethyl, isopropyl, t-butyl or phenyl and R7 is 1hydroxyethyl, methyl or hydroxymethyl. 4. A compound according to Claim l wherein R8 is selected from the group consisting of: H, CH3, (CH2)2NH2, C(CH3)2CH2NH2 EMI77.1 EMI78.1 CH2CH2CH2NH2, CH2CH(CH3)NH2, EMI78.2 EMI79.1 EMI80.1 CH(CH3)CH2NH2 EMI80.2 5. A compound according to Claim 4 wherein R6 is H or methyl; R7 is selected from: EMI80.3 EMI81.1 -CH3 -CH2CH3 EMI81.2 and R1 and R2 are selected from spirocyclopropyl; phenyl; cycloalkyl having 3-6 carbon atoms; alkyl having 1-6 carbon atoms; cyclopropylalkyl having 4-9 carbon atoms. 6. A compound according to Claim 1 selected from the group consisting of: EMI81.3 EMI82.1 (R - phenyl, m-aminomethylphenyl, o-, p-, m-hydroxyphenyl; R' is phenyl) EMI83.1 EMI84.1 EMI85.1 7. A compound according to Claim 6 wherein the aminoethylthio side chain, EMI86.1 is replaced by a member of the group consisting of: EMI86.2 n= 1, 3, 4, 5 or 6. 8. The compound of the formula: EMI87.1 wherein R is H or a readily removable protecting group; and wherein RÚ, Rê, R6, and R7 are independently selected from the group consisting of hydrogen, (P and R2 are not bothhydrogen), substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; spirocycloalkyl having 3-6 carbon atoms; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the alkyl chain has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl wherein the substituent or substituents relative to the above-named radicals are selected from the group consisting of: amino, mono-, di-, and trialkylamino, hydroxyl, alkoxyl, mercapto, alkylthio, phenylthio, sulfamovl, amidino, guanidino, nitro, chloro, bromo, fluoroiodp, cyano and carboxy; and wherein the hetero atom or atoms in the above-named heterocyclic moieties are selected from the group consisting of 1-4 oxygen, nitrogen or sulphur atoms; and wherein the alkyl moieties of the above-recited substituents have 1-6 carbon atoms. 9. The compound of Claim 8 wherein R is triloweralkylsilyl, wherein the alkyl moieties have from 1 to 6 carbon atoms. 10. A compound of the formula: EMI88.1 wherein R is hydrogen Dr a readily removable protect 7 6 1 and 2 ting group; and whereln R, R, R, and R are independently selected from the group consisting of hydrogen, (R1 and R2 are not both hydrogen), substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; spirocycloalkyl having 3-6 carbon atoms; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the-aryl moiety is phenyl and the alkyl chain has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl wherein the substituent or substituents relative to the above-named radicals are selected from the group consisting of: amino, mono-, di-, and trialkylamino, hydroxyl, alkoxyl, mercapto, alkylthio, phenylthio, sulfamoyl, amidino, guanidino, nitro, chloro, bromo, iodo, fluoro, cyano and carboxy;: and wherein the hetero atom or atoms in the above-named heterocyclic moieties are selected from the group consisting of 1-4 oxygen, nitrogen or sulphur atoms; and wherein the alkyl moieties of the above-recited substituents have 1-6 carbon atoms. 11. A compound of the formula: EMI89.1 wherein RO is hydrogen, a salt cation, a pharmaceutically acceptable ester moiety, or a readily removable protecting group; and wherein R71 R, Pl and R are independently selected from the group consisting of hydrogen, (R1 and R2 are not both hydrogen), substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; spirocycloalkyl having 3-6 carbon atoms; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the arly moiety is phenyl and the alkyl chain has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl wherein the substituent or substituents relative to the abovenamed radicals are selected from the group consisting o.-: amino mono-, di-, and trialkylamino, hydroxyl, alkoxy, ercapto, alkylthio, phenylthio, sulfamoyl, amidino, guanidino, nitro, chloro, bromoiodo, fluoro, cyano and carboxy; and wherein the hetero atom or atoms in the above-named heterocyclic moieties are selected from the group consisting of 1-4 oxygen, nitrogen or sulphur atoms; and wherein the alkyl moieties of the above-recited substituents have 1-6 carbon atoms. 12- A process for preparing: EMI90.1 comprising: oxidizing EMI90.2 to form: EMI90.3 followed by treating with R9O2CCH2CO2 ; wherein R9 is a pharmaceuticaily acceptable ester moiety or a readily removable protecting group. 13 The process of Claim 12 wherein 9 R902CCH2Co2 is utilized as (R902CCH2CO2)2Mg. 14. A process for preparing a compound of Claim 1 having the structure: EMI91.1 and the pharmaceutically acceptable salts and esters thereof comprising the steps of activating and then treating with the thio reagent HSR8 a compound of the formula EMI91.2 wherein R6, R , R , R2, and R8 are defined by independent Claim 1 and R is a pharmaceutically acceptable ester moiety or a readily removable carboxyl protecting group. 15 An antibiotic pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claim 1 and a pharmaceutioal carrier therefor. 16. A compound having the structure: EMI92.1 and the pharmaceutically acceptable salts and esters thereof; wherein R , R2, R6, R7 and R8 are independently selected from the group consisting of hydrogen, and substituted and unsubstituted: alkyl having 1-6 carbon atoms, aralkyl, alkenyl and alkynyl having 2-6 carbon atoms, aryl and aralkyl having 6-10 ring carbon atoms and 1-6 carbon atoms in the alkyl chain, heterocyclyl, heterocyclylthio (Re is excluded) and heterocyclylalkyl having 1-5 hetero atoms selected from 0, N or S in the ring and 1-6 carbon atoms in the alkyl chain, cycloalkyl, spirocycloalkyl, and cycloalkylalkyl having 3 to 6, ring carbon atoms and 1-6 carbon atoms in the alkyl moiety; wherein the substituents on RÚ, R2, R , R and P6 are selected from chloro, bromo, fluoro, iodo, hydroxyl, amino, mono-, di- and trialkyl substituted amino (each alkyl having 1-6 carbon atomsl alkoxyl having 1-6 carbon atoms, guanidino, cyano, amidino and carboxyl; with the proviso that and and R are not hydrogen. 17. A compound according to Claim16 wherein R1 and R2 are alkyl, having 1-6 carbon atoms, spirocyclopropyl, benzyl or phenyl; R6 is hydrogen and R7 is substituted or unsubstituted: alkyl having 1-6 carbon atoms or phenylalkyl; wherein the substituent is OH or NH2; and R8 is selected from: EMI93.1 18. A compound according to Claim 17wherein P 1 and P 2 R and R are methyl, ethyl, isopropyl, cyclopropyl, t- butyl or phenyl; R7 is l-hydroxyethyl, methyl, or hydroxymethyl; and R6 is hydrogen. 1.9. A compound according to Claims 1 - 18 wherein R8 is selected from the group consisting of: hydrogen, -CH2CH2CH2NH2, -CH2CH2NH2, -CH3, -CH2CH2CH2OH, -CH2CH2COOH, EMI94.1 EMI95.1 20. A compound according to Claim 19 wherein R and R 2 are alkyl having 1-6 carbon atoms, phenyl, cyclopropyl, or spirocyclopropyl. 21. A compound according to Claim 16 selected from: EMI96.1 EMI97.1 22. A process for preparing a compound according to Claim 16 comprising cyclizing: EMI98.1 wherein is phenyl, and Rb is a pharmaceutically acceptable ester moiety or a readily removable blocking group. 23. A process for preparing a compound according to Claim 16comprising oxidizing: EMI98.2 to form EMI98.3 followed by activating and treating with carbon neucleophile to establish R3 EMI98.4 followed by N-deprotecting and treating with a glyoxyalate to yield EMI99.1 followed by activating and treating with a triorganophosphine to form EMI99.2 followed by cyclizing and deprotecting wherein R is a readily removable protecting group; R' is a readily removable protecting group r pharmaceutically acceptable ester moiety; and R" z loweralkyl or phenyl. 24. An antibiotic pharmaceutical composition comprising a therapeutically effective amount of a compound according to Claims 16-22 and a pharmaceutical carrier there for. 25. A compound having the formula: EMI100.1 and its pharmaceutically acceptable salts and esters wherein R1 and R2 are selected from the group consisting of substituted and unsubstituted: loweralkyl having from 1-6 carbon atoms, phenyl, phenyllower- alkyl1 cycloalkyl having from 3 to 6 carbon atoms, cycloalkylalkyl having 1 to 7 carbon atoms in the chain and 3-6 carbon atoms in the ring and spirocycloalkyl having 3-6 carbon atoms; wherein said substituents on R1 and R2 are selected from the group consisting of halogen, hydroxy, amino, and substituted amino, azido, cyano, carboxyl, alkoxyl, and mono-, di- and trialkylamino, each alkyl radical of the foregoing having 1-6 carbon atoms 26. A compound according to Claim 25wherein R1 and R2 are selected from methyl,.phenyl, ethyi, cyclopropyl, propyl, isopropyl, and spiro-cyclopropyl. 27. A compound having the structure: EMI101.1 and the pharmaceutically acceptable salts and esters thereof; wherein R1, R , R and R are independently selected from the group consisting of hydrogen, and substituted and unsubstituted: alkyl having 1-6 carbon atoms; phenyl; phenylalkyl wherein the alkyl moiety has 1-6 carbon atoms; cycloalkyl and cycloalkylalkyl having 3 to 6 ring carbon atoms and 1-6 carbon atoms in the alkyl moiety; and spirocycloalkyl having 3 to 6 carbon atoms; wherein the substituent or substituents on 1 R2, R6 and R7 are selected from chloro, bromo, fluoro, hydroxyl, amino, mono-, di-, and trialkylamino (each alkyl having 1-6 carbon atoms), alkoxyl having 1-6 carbon atoms, cyano and carboxyl; wherein Rl and R2 are not hydrogen. 28. A compound according to Claim 27 wherein RÚ and Rê are selected from: alkyl cyclopropyl, spirocyclopropyl, and benzyl and phenyl; R6 is alkyl and phenylalkyl substituted by hydroxyl or amino; and R is hydrogen or alkyl or phenylalkyl substituted by hydroxyl or amino. 29. A compound according to Claim 28wherein R1 and R2 are selected from: methyl, ethyl, isopropyl, 6 t-butyl, spirocyclopropyl, or phenyl; R is l-hydroxy- ethyl, methyl, or hydroxymethyl; and R7 is hydrogen. 30. A compound according to Claim 27 having the structure: EMI102.1 31. A compound according to Claim 27having the structure: EMI102.2 Claims for Austria 1. A process for preparing: EMI103.1 comprising: oxidizing EMI103.2 to form: EMI103.3 followed by treating with R9O2CCH2CO2 ; wherein RÚ, Rê, R6, and R7 are independently selected from the group consisting of hydrogen, (RÚ and Rê are not hydrogen), substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; t cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties7 spirocycloalkyl having 3-6 carbon atoms; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the alkyl chain has 1-6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl wherein the substituent or substituents relative to the above-named radicals are selected from the group consisting of: amino, mono-, di-, and trialkylamino, hydroxyl, alkoxyl, mercapto, alkylthio, phenylthio, sulfamoyl, amidino, guanidino, nitro, chloro, bromo, fluoXoiodot cyano qnd carboxy; and wherein the hetero atom or atoms in the above-named heterocyclic moieties are selected from the group consisting of 1-4 oxygen, nitrogen or sulphur atoms; and wherein the alkyl moieties of the above-recited substituents have 1-6 carbon atoms; R9 is a pharmacentically acceptable ester moiety or a. readily removable protecting group and Rio is hydrogen or a readily removable protecting group. 2. The process of Claim 1 wherein R902CCH2Co2e is utilized as (R9O2CCH2CO2) 2Mg 3. A process for preparing a compound having the structure: EMI104.1 and the pharmaceutically acceptable salts and esters thereof comprising the steps of activating and then treating with the thio reagent HSR8 a compound of the formula There is a continuing need for new antibiotics; for unfortunately, there is no static effectiveness of any given antibiotic because continued wide scale usage selectively gives rise to resistant strains of pathogens. in addition, the known antibiotics suffer from the disadvantage of being effective only against certain types of microorganisms. Accordingly, the search for new antibiotics continues. Thus, it is an objection of the present invention to provide a novel class of antibiotics which are useful in animal and human therapy and in inanimate systems. These antibiotics are active against a broad range of pathogens which representaively include both gram positive bacteria such as S. aureua, Strep. pyogenes, and B. subtilis, and gram negative bacteria such as E. coli, Pseudomonas, Proteus morganii, Serratia, and Klebsiella. Further objects of this invention are to provide chemical processes for the preparation of such antibiotics and their non-toxic pharmaceutically acceptable salts; pharmaceutical compositions comprising such antibiotics; and to provide methods of treatment comprising administering such antibiotics and compositions when an antibiotic effect is indicated. Incorporation by Reference The following pending U.S. Patent Applications of Christensen and Shih have been combined to form the present application. To the extent that these co-pending applications describe the final products I, their utility and their manner of preparation, they are hereby incorporated by reference: 1.) U.S. Serial Number 099,400 - Filed December 3, 1979. 1 ,l-Disubstituted-pen-2 -em-3-carboxylic acids 2.) U.S. Serial Number 099,285- Filed December 3, 1979 6- and 1, l-Disubstituted-l-carbadethiapen-2- em-3-carboxylic acid 3.) U.S. Serial Number 099,275 - Filed December 3, 1979 6-, 1- and 2-substituted-l-carbadethiapen-2 em-3-carboxylic acids 4.) U.S. Serial Number 099,451 - Filed December 3, 1979 1-, 6- and 2-substituted-l-carba-2-penem-3 carboxylic acids EMI107.1 and the pharmaceutically acceptable salts and esters thereof; wherein R1, R2, R6, R 7 and R6 are independently selected from the group consisting of hydrogen, and substituted and unsubstituted: alkyl having 1-6 carbon atoms, aralkyl, akenyl and alkynyl having 2-6 carbon atoms, aryl and aralkyl having 6-10 ring carbon atoms and 1-6 carbon atoms in the alkyl chain, heterocyclyl, heterocyclylthio (R8 is excluded) and heterocyclylalkyl having 1-5 hetero atoms selected from 0, N or S in the ring and 1-6 carbon atoms in the alkyl chain, cycloalkyl, spirocycloalkyl, and cycloalkylalkyl having 3 to 6, ring carbon atoms and 1-6 carbon atoms in the alkyl moiety; wherein the substituents on RÚ, R , R P 7 and R are selected from chloro, bromo fluoro, iodo, hydroxyl, amino, mono-, ai- and trialkyl substituted amino (each alkyl having 1-6 carbon atoms) alkoxyl having 1-6 carbon atoms, guanidino, cyano, amidino and carboxyl; with the proviso that p1 and not are not hydrogen; and comprising oxidizinq: EMI107.2 to form EMI107.3 followed. by activating and treating with carbon neucleophile to establish R3 EMI108.1 followed by N-deprotecting and treating with a glyoxyalate to yield EMI108.2 followed by activating and treating with a triorganophosphine to form EMI108.3 followed by cyclizing and deprotecting wherein R is a readily removable protecting group; R' is a readily removable protecting group Cr pharmaceutically acceptable ester moiety; and R'' z loweralkyl or phenyl.

Inventors: CHRISTENSEN, BURTON G., SHIH, DAVID H.
Applicants: MERCK & CO. INC.
Application year: 1980
Main classification: C07D487
IPC codes: C07C17, C07F7, C07C1, C07F9, C07D477, C07D205